O

Otonomy Inc
F:7OT

Watchlist Manager
Otonomy Inc
F:7OT
Watchlist
Price: 0.0626 EUR 0.64% Market Closed
Market Cap: 11.4m EUR

Gross Margin
Otonomy Inc

0%
Current
-159%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
0%
=
Gross Profit
0
/
Revenue
0

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Otonomy Inc
F:7OT
11.4m EUR N/A
US
Eli Lilly and Co
NYSE:LLY
1.1T USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
500.7B USD
68%
CH
Roche Holding AG
SIX:ROG
269.6B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
221.5B GBP
82%
CH
Novartis AG
SIX:NOVN
219.5B CHF
76%
US
Merck & Co Inc
NYSE:MRK
277.7B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
144.7B USD
75%
No Stocks Found

Otonomy Inc
Glance View

Market Cap
11.4m EUR
Industry
Pharmaceuticals

Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

7OT Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
0%
=
Gross Profit
0
/
Revenue
0
What is the Gross Margin of Otonomy Inc?

Based on Otonomy Inc's most recent financial statements, the company has Gross Margin of 0%.

Back to Top